- Home
- RNG vs CNTA Comparison
RNG vs CNTA Comparison
Compare RNG & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RNG | CNTA |
|---|---|---|
| Founded | 1999 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 6.1B |
| IPO Year | 2013 | 2021 |
Fundamental Metrics
Financial Performance| Metric | RNG | CNTA |
|---|---|---|
| Price | $39.67 | $39.50 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 14 | 9 |
| Target Price | $33.58 | ★ $43.17 |
| AVG Volume (30 Days) | 1.4M | ★ 4.9M |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | ★ 0.74% | N/A |
| EPS Growth | ★ 176.19 | 29.13 |
| EPS | ★ 0.48 | N/A |
| Revenue | ★ $2,515,142,000.00 | $15,000,000.00 |
| Revenue This Year | $5.56 | N/A |
| Revenue Next Year | $4.56 | N/A |
| P/E Ratio | $84.60 | ★ N/A |
| Revenue Growth | ★ 4.78 | N/A |
| 52 Week Low | $23.59 | $10.95 |
| 52 Week High | $43.83 | $40.26 |
Technical Indicators
Market Signals| Indicator | RNG | CNTA |
|---|---|---|
| Relative Strength Index (RSI) | 54.09 | 73.71 |
| Support Level | $25.56 | $39.16 |
| Resistance Level | $43.13 | $40.26 |
| Average True Range (ATR) | 2.24 | 0.22 |
| MACD | 0.07 | -0.45 |
| Stochastic Oscillator | 61.55 | 52.34 |
Price Performance
Historical ComparisonAbout RNG RingCentral Inc.
RingCentral is a unified communications as a service, or UCaaS, provider. Its software helps users communicate and collaborate via voice, video, and messaging across all device types and all from one platform. RingCentral helps customers modernize and move from legacy on-premises systems to modern, cloud-based systems. Beyond its core RingCentral MVP solution, RingCentral also offers a cloud-based contact center solution, a stand-alone video meetings solution, and webinars.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage biotechnology company pioneering a new class of therapeutics in orexin-based neuroscience. The group is developing a franchise of small molecule orexin receptor 2 (OX2R) agonists designed to address neuroscience diseases underpinned by dysregulation of wakefulness, attention, cognition, mood, and other symptoms, each grounded in the shared biology of the orexin pathway. The company's programs and Pipeline are the Orexin Receptor 2 Agonist Program and LockBody Technology Platform.